Stereotactic Body Radiation Therapy in Hepatocellular Carcinoma

Gagan Saini

doi:10.4103/ijmpo.ijmpo_67_20

Indian Journal of Medical and Paediatric Oncology, Table of Contents

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(04): 488-491
DOI: 10.4103/ijmpo.ijmpo_67_20

Editorial Commentary

Stereotactic Body Radiation Therapy in Hepatocellular Carcinoma

Gagan Saini

Department of Radiation Oncology, Max Institute of Cancer Care, Delhi NCR, India

› Author Affiliations

Abstract

Full Text

References

References
1 Tummala KS, Brandt M, Teijeiro A, Graña O, Schwabe RF, Perna C. et al. Hepatocellular carcinomas originate predominantly from hepatocytes and benign lesions from hepatic progenitor cells. Cell Rep 2017; 19: 584-600
2 Acharya SK. Epidemiology of hepatocellular carcinoma in India. J Clin Exp Hepatol 2014; 4: S27-33
3 Kumar R, Kumar Saraswat M, Chander Sharma B, Sakhuja P, Sarin SK. Characteristics of hepatocellular carcinoma in India: A retrospective analysis of 191 cases. QJM 2008; 101: 479-85
4 Guckenberger M, Andratschke N, Alheit H, Holy R, Moustakis C, Nestle U. et al. Definition of stereotactic body radiotherapy: Principles and practice for the treatment of stage I non-small cell lung cancer. Strahlenther Onkol 2014; 190: 26-33
5 Wahl DR, Stenmark MH, Tao Y, Pollom EL, Caoili EM, Lawrence TS. et al. Outcomesww after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol 2016; 34: 452-9
6 Rajyaguru DJ, Borgert AJ, Smith AL, Thomes RM, Conway PD, Halfdanarson TR. et al. Radiofrequency ablation versus stereotactic body radiotherapy for localized hepatocellular carcinoma in nonsurgically managed patients: Analysis of the national cancer database. J Clin Oncol 2018; 36: 600-8
7 Bibault JE, Dewas S, Vautravers-Dewas C, Hollebecque A, Jarraya H, Lacornerie T. et al. Stereotactic body radiation therapy for hepatocellular carcinoma: Prognostic factors of local control, overall survival, and toxicity. PLoS One 2013; 8: e77472
8 Andolino DL, Johnson CS, Maluccio M, Kwo P, Tector AJ, Zook J. et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2011; 81: e447-53
9 Jung J, Yoon SM, Kim SY, Cho B, Park JH, Kim SS. et al. Radiation-induced liver disease after stereotactic body radiotherapy for small hepatocellular carcinoma: Clinical and dose-volumetric parameters. Radiat Oncol 2013; 8: 249
10 Sanuki N, Takeda A, Mizuno T, Oku Y, Eriguchi T, Iwabuchi S. et al. Tumor response on CT following hypofractionated stereotactic ablative body radiotherapy for small hypervascular hepatocellular carcinoma with cirrhosis. AJR Am J Roentgenol 2013; 201: W812-20
11 Higgins H, Berger DL. RFA for liver tumors: Does it really work?. Oncologist 2006; 11: 801-8
12 Méndez Romero A, Wunderink W, Hussain SM, De Pooter JA, Heijmen BJ, Nowak PC. et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study. Acta Oncol 2006; 45: 831-7
13 Kang JK, Kim MS, Cho CK, Yang KM, Yoo HJ, Kim JH. et al. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer 2012; 118: 5424-31
14 Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RK. et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 2013; 31: 1631-9
15 Culleton S, Jiang H, Haddad CR, Kim J, Brierley J, Brade A. et al. Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma. Radiother Oncol 2014; 111: 412-7
16 Scorsetti M, Comito T, Cozzi L, Clerici E, Tozzi A, Franzese C. et al. The challenge of inoperable hepatocellular carcinoma (HCC): Results of a single-institutional experience on stereotactic body radiation therapy (SBRT). J Cancer Res Clin Oncol 2015; 141: 1301-9
17 Huo YR, Eslick GD. Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma: A systematic review and meta-analysis. JAMA Oncol 2015; 1: 756-65
18 Buckstein M, Kim E, Fischman A, Blacksburg S, Facciuto M, Schwartz M. et al. Stereotactic body radiation therapy following transarterial chemoembolization for unresectable hepatocellular carcinoma. J Gastrointest Oncol 2018; 9: 734-40
19 Hoekstra J, Janssen HL. Vascular liver disorders (II): Portal vein thrombosis. Neth J Med 2009; 67: 46-53
20 Lin CS, Jen YM, Chiu SY, Hwang JM, Chao HL, Lin HY. et al. Treatment of portal vein tumor thrombosis of hepatoma patients with either stereotactic radiotherapy or three-dimensional conformal radiotherapy. Jpn J Clin Oncol 2006; 36: 212-7
21 Xi M, Zhang L, Zhao L, Li QQ, Guo SP, Feng ZZ. et al. Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombosis. PLoS One 2013; 8: e63864
22 Kang J, Nie Q, DU R, Zhang L, Zhang J, Li Q. et al. Stereotactic body radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis. Mol Clin Oncol 2014; 2: 43-50
23 Sapisochin G, Barry A, Doherty M, Fischer S, Goldaracena N, Rosales R. et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol 2017; 67: 92-9
24 Nugent FW, Qamar A, Stuart KE, Galuski K, Flacke S, Molgaard C. A randomized phase II study of individualized stereotactic body radiation therapy (SBRT) versus transarterial chemoembolization (TACE) with DEBDOX beads as a bridge to transplant in hepatocellular carcinoma (HCC). J Clin Oncol 2017; 35 et al. suppl 4S abstract 223 223